Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease

US11878970B2 · kind B2 · utility

Assignee

• PETRA PHARMA CORPORATION · US

Inventors

• Erin Danielle ANDERSON · Boulder, US
• Sean Aronow · Boulder, US
• Nicholas Boyles · Hillsboro, US
• Xiaohong Chen · Broomfield, US
• Surendra DAWADI · Chesterfield, US
• Eugene Richard Hickey · Danbury, US
• Thomas Combs IRVIN · Erie, US
• Edward A. Kesicki · Bothell, US
• Gabrielle R. Kolakowski · Boulder, US
• Jennifer Lynn KNIGHT · Jersey City, US
• Manoj KUMAR · Longmont, US
• Katelyn Frances LONG · Lafayette, US
• Christopher Mayne · Boulder, US
• Johnathan Alexander McLean · Indianapolis, US
• Gerit Maria POTOTSCHNIG · San Diego, US
• Hua Wang · Columbus, US
• Michael Brian WELCH · Westminster, US
• Tien WIDJAJA · Lafayette, US

Key dates

• Filing date: May 26, 2022
• Grant date: Jan 23, 2024
• Expiry date: May 26, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.